Intervacc AB (SE:IVACC)
:IVACC
Want to see SE:IVACC full AI Analyst Report?
Top Page
Intervacc AB
(IVACC)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr1.50
▲(63.04% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by very weak financial performance (negative gross profit, extreme operating losses, and significant ongoing cash burn), partially offset by a strong low-leverage balance sheet and moderately constructive technical momentum. Valuation does not provide support due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Low leverage & substantial equity
A very low debt profile combined with SEK 253.2M of equity gives the company financing optionality and lowers refinancing risk. This balance-sheet strength supports continued R&D and commercialization investments and cushions operational setbacks over the next several quarters.
Negative Factors
Heavy ongoing cash burn
Very large negative operating and free cash flow are structural risks: they deplete reserves and force recurring external funding or dilution. Persistent cash burn constrains investment in commercialization, heightens financing risk, and can limit the company’s ability to respond to competitive or regulatory demands.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage & substantial equity
A very low debt profile combined with SEK 253.2M of equity gives the company financing optionality and lowers refinancing risk. This balance-sheet strength supports continued R&D and commercialization investments and cushions operational setbacks over the next several quarters.
Read all positive factors
Intervacc AB (IVACC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr435.56M
Dividend YieldN/A
Average Volume (3M)373.34K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth35.23%
EPS Growth64.44%
CountrySE
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr44.00M
Intervacc AB Business Overview & Revenue Model
Company Description
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for ...
How the Company Makes Money
Intervacc makes money primarily by selling veterinary vaccines, with revenue driven mainly by commercial sales of its equine vaccine Strangvac through distribution and commercialization partners in approved markets. The company’s earnings are ther...
Intervacc AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.89M | 20.09M | 11.79M | 8.02M | 9.68M | 5.24M |
| Gross Profit | -73.90M | -84.86M | -3.53M | -13.81M | 3.37M | 6.25M |
| EBITDA | -73.99M | -66.25M | -58.75M | -68.98M | -57.73M | -23.15M |
| Net Income | -89.37M | -80.81M | -75.52M | -102.85M | -64.16M | -29.38M |
Balance Sheet | ||||||
| Total Assets | 278.23M | 294.43M | 187.32M | 259.61M | 265.04M | 329.39M |
| Cash, Cash Equivalents and Short-Term Investments | 145.63M | 160.89M | 34.40M | 88.34M | 45.70M | 115.71M |
| Total Debt | 357.00K | 0.00 | 145.00K | 181.00K | 322.00K | 433.00K |
| Total Liabilities | 25.04M | 19.52M | 24.99M | 21.68M | 14.88M | 21.14M |
| Stockholders Equity | 253.19M | 274.91M | 162.33M | 237.93M | 250.16M | 308.25M |
Cash Flow | ||||||
| Free Cash Flow | -67.24M | -66.92M | -53.90M | -47.94M | -75.92M | -48.67M |
| Operating Cash Flow | -65.70M | -65.79M | -53.20M | -45.83M | -69.79M | -25.46M |
| Investing Cash Flow | -5.02M | -1.13M | -706.00K | -2.11M | -6.13M | -23.13M |
| Financing Cash Flow | 254.00K | 193.40M | -36.00K | 90.58M | 5.91M | 50.00K |
Intervacc AB Technical Analysis
Positive
0.92
Price Trends
1.05
Positive
0.93
Positive
0.97
Positive
Market Momentum
0.05
Positive
54.93
Neutral
53.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Positive. The current price of 0.92 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.05, and below the 200-day MA of 0.97, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 54.93 is Neutral, neither overbought nor oversold. The STOCH value of 53.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IVACC.
Intervacc AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr343.52M | -3.24 | -16.51% | ― | ― | 22.09% | |
49 Neutral | kr226.66M | 2.17 | -16.90% | ― | -72.49% | ― | |
48 Neutral | kr435.56M | -4.67 | -25.80% | ― | 35.23% | 64.44% | |
47 Neutral | kr413.59M | -5.73 | -79.60% | ― | ― | 51.40% | |
43 Neutral | kr109.23M | -1.59 | -199.86% | ― | -6.59% | 27.05% | |
41 Neutral | kr218.41M | -10.07 | -59.78% | ― | ― | 43.30% |
* Healthcare Sector Average
SE:IVACC
Intervacc AB
1.22
0.16
15.25%
SE:XBRANE
Xbrane Biopharma AB
11.15
-15.78
-58.59%
SE:ELIC
Elicera Therapeutics AB
3.00
-3.26
-52.11%
SE:ACE
Ascelia Pharma AB
3.20
-1.09
-25.49%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.30
-5.81
-81.77%
SE:IMMU
Immunicum AB
5.48
0.45
8.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.